Pharmacokinetics and pharmacodynamics of levodopa

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the short plasma half-life of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels, the so-called short-duration response. These features are the basis of motor fluctuations that complicate long-term therapy with levodopa. Motor fluctuations will predictably improve with measures that prolong the elevations of plasma levodopa or prolong the efficacy of dopamine synthesized from exogenous levodopa. Because dyskinesia is closely linked to the short-duration response and conceivably part of the short-duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations.

Original languageEnglish (US)
JournalMovement Disorders
Volume23
Issue numberSUPPL. 3
DOIs
StatePublished - 2008

Fingerprint

Levodopa
Pharmacokinetics
Dyskinesias
Antiparkinson Agents
Half-Life
Dopamine
Therapeutics
Pharmaceutical Preparations

Keywords

  • Dyskinesia
  • Levodopa
  • Motor fluctuations
  • Short-duration response

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Pharmacokinetics and pharmacodynamics of levodopa. / Nutt, John.

In: Movement Disorders, Vol. 23, No. SUPPL. 3, 2008.

Research output: Contribution to journalArticle

@article{022cbef2e0cd40e3b2e7b282c86cf51d,
title = "Pharmacokinetics and pharmacodynamics of levodopa",
abstract = "The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the short plasma half-life of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels, the so-called short-duration response. These features are the basis of motor fluctuations that complicate long-term therapy with levodopa. Motor fluctuations will predictably improve with measures that prolong the elevations of plasma levodopa or prolong the efficacy of dopamine synthesized from exogenous levodopa. Because dyskinesia is closely linked to the short-duration response and conceivably part of the short-duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations.",
keywords = "Dyskinesia, Levodopa, Motor fluctuations, Short-duration response",
author = "John Nutt",
year = "2008",
doi = "10.1002/mds.22037",
language = "English (US)",
volume = "23",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics of levodopa

AU - Nutt, John

PY - 2008

Y1 - 2008

N2 - The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the short plasma half-life of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels, the so-called short-duration response. These features are the basis of motor fluctuations that complicate long-term therapy with levodopa. Motor fluctuations will predictably improve with measures that prolong the elevations of plasma levodopa or prolong the efficacy of dopamine synthesized from exogenous levodopa. Because dyskinesia is closely linked to the short-duration response and conceivably part of the short-duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations.

AB - The pharmacokinetics and pharmacodynamics of levodopa are dominated by two features: the short plasma half-life of the drug and the portion of the antiparkinsonian response that parallels the plasma levodopa levels, the so-called short-duration response. These features are the basis of motor fluctuations that complicate long-term therapy with levodopa. Motor fluctuations will predictably improve with measures that prolong the elevations of plasma levodopa or prolong the efficacy of dopamine synthesized from exogenous levodopa. Because dyskinesia is closely linked to the short-duration response and conceivably part of the short-duration response, it is less clear that dyskinesia will be improved by therapeutic strategies that reduce motor fluctuations.

KW - Dyskinesia

KW - Levodopa

KW - Motor fluctuations

KW - Short-duration response

UR - http://www.scopus.com/inward/record.url?scp=53149144682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53149144682&partnerID=8YFLogxK

U2 - 10.1002/mds.22037

DO - 10.1002/mds.22037

M3 - Article

C2 - 18781675

AN - SCOPUS:53149144682

VL - 23

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - SUPPL. 3

ER -